GlassScriptPhysician profile
Relfa Proano
NPI 1861189318
$2,519.66
in general payments reported to CMS, 2019-2025
21 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $280 · 2024: $970 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $580.26 | 2023-2025 | Briviact, Nayzilam, Rystiggo |
| Jazz Pharmaceuticals INC. | $248.88 | 2024-2025 | |
| Amgen INC. | $238.45 | 2024-2025 | Tepezza, Uplizna |
| Emd Serono, INC. | $177.14 | 2023-2024 | Mavenclad, Mavenclad |
| Livanova USA, INC. | $160.09 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $139.45 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $125.00 | 2023 | Xcopri |
| Biogen, INC. | $124.35 | 2024-2025 | Skyclarys, Vumerity, Tysabri |
| Abbvie INC. | $96.04 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $83.49 | 2023-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $83.22 | 2024-2025 | Acthar |
| Teva Pharmaceuticals USA, INC. | $78.18 | 2024 | Austedo Xr, Ajovy |
| Takeda Pharmaceuticals U.S.A., INC. | $77.34 | 2024-2025 | Hyqvia |
| Lundbeck LLC | $75.12 | 2023 | Vyepti |
| Pfizer INC. | $61.42 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $46.34 | 2024-2025 | Ocrevus, Tnkase |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $42.54 | 2025 | Rejoyn |
| Astrazeneca Pharmaceuticals LP | $25.53 | 2025 | Wainua |
| Amneal Pharmaceuticals LLC | $22.42 | 2025 | Crexont |
| Novo Nordisk INC | $18.87 | 2025 | Wegovy |
| Merz Pharmaceuticals, LLC | $15.53 | 2025 | Ampyra, Inbrija, Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Relfa Proano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.